Deal Library / Pharma BD Deal Intelligence

Valeant Pharmaceuticals International, Inc. — Pharma Deals

The Pharma Closeout tracks 9 deals, $17.2B in disclosed deal value, 8 with a post-close Outcome Score for Valeant Pharmaceuticals International, Inc..

Median Critic Score: 71  ·  Median Outcome Score: 36

Best outcome: Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. (66)  ·  Weakest outcome: Valeant Pharmaceuticals International, Inc. / Biovail Corporation (18)

All 9 deals

• Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. — 2009 · $285M · Largely worked — most objectives met.
• Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals — 2011 · $700M · Largely worked — most objectives met.
• Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. — 2005 · $280M · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals International, Inc. / Bausch + Lomb — 2013 · $8.7B · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) — 2011 · $425M · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation — 2012 · $2.6B · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. — 2014 · $475M · Did not work — the deal failed to deliver.
• Valeant Pharmaceuticals International, Inc. / Biovail Corporation — 2010 · $3.3B · Did not work — the deal failed to deliver.
• Valeant Pharmaceuticals International, Inc. / Sanitas — 2011 · $440M

← Deal Library  ·  Interactive search  ·  How we score deals